PDE4D inhibition by rAAV9 injection or the pharmacological inhibitor roflumilast shows protection against cardiac hypertrophy and dysfunction through promoting cAMP, cAMP response element binding (CREB), and NAD-dependent deacetylase sirtuin 1 signaling for SERCA2a expression (83). The gene discussed is PDE4D; the disease is cardiac hypertrophy.